Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X about a paper by Nickolas Stabellini et al. published in Breast Cancer Research and Treatment:
“Do we always need full dose ADCs to achieve benefit?
In a 🇺🇸retrospective RWE cohort of previously treated mBC, starting T-DXd (n=66) or SG (n=48) at reduced dose was associated with similar PFS, OS, and ORR vs standard dosing
Not practice changing, but a clinically meaningful signal that merits further study.
Well done work on a practical clinical question.”
Title: Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study
Authors: Nickolas Stabellini, Jasskiran Kaur, Cynthia Owusu, Bahar Moftakhar, Takae Mizukami, Sonia D. de Oliveira, Alberto J. Montero
You can read the Full Article in Breast Cancer Research and Treatment.
More posts featuring Oscar Tahuahua.